Spero's Oral Tebipenem HBr Stacks Up To IV Carbapenem In Phase III

Tebipenem HBr, a potential first oral carbapenem antibiotic, will be submitted to the US FDA under a rolling NDA in the first quarter of 2021 for complicated urinary tract infection and acute pyelonephritis.